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1. Introduction
  The leishmaniasis has been considered as tropical 
affliction that together constitutes one of the six entities on 
the World Health Organization tropical disease research 
list of most important disease[1]. It occurs in 88 countries 
in tropical and temperate regions, 72 of them developing or 
least developed. The annual global prevalence of all form of 
leishmaniasis is approximately two millions. However, there 
is a gross under reporting of the cases from endemic regions 
in developing countries like India, Nepal and Bangladesh. 
New cases are often being reported from newer areas mainly 
due to population migration from endemic to non-endemic 
regions [2]. Indian kala-azar or visceral leishmaniasis, 
caused by Leishmania donovani (L. donovani), is a 
potentially fatal disease. It is endemic in eastern part of 
India and often turns epidemic. Out of 500 000 new cases of 
VL that occurs every year worldwide, about 100 000 cases of 
VL are estimated to occur annually in India[3].
The state of Bihar accounts for more than 90% of the cases 
and other affected area includes the states of Assam, West 
Bengal and eastern part of Uttar Pradesh[4]. 
  The successful management of leishmaniasis requires 
an early and accurate diagnosis as well as a test of cure to 
confirm the final status of disease. Various serological tests 
based on serum antibodies detection like rk39 strip test, 
ELISA and direct agglutination test (DAT) are being used to 
diagnose VL with high sensitivity but their specificity is very 
poor in disease endemic areas[5]. Moreover, the prognostic 
capabilities of the current methods is highly compromised 
because anti-leishmanial antibodies may persist in the 
serum for extended period even after successful treatment, 
which limit their use in the diagnosis of past infections, 
reinfections, relapse and as a test of cure[5, 6]. So a specific 
test that could be used for both, diagnostic and prognostic 
purpose is still required.
  The presence of parasitic antigens released in urine can 
be linked to the level of renal physiology as well as status 
of infection present in the host. In addition, the urinary 
antigens may be also useful in diagnostic and prognostic 
purposes. The diagnostic capabilities of urinary antigens 
have been reported in various infectious diseases like 
schistosomiasis[7], malaria[8], Chagas disease[9] and rever 
blindness[10]. The presence of soluble urinary leishmanial 
antigens in visceral leishmaniasis has been successfully 
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reported in various studies however, their characterization 
has not been done in most of the cases[11-14]. This study was 
done to detect the antigens of leishmanial origin in pre and 
post treatment urine samples of VL patients and to evaluate 
their seropositivity.
2. Materials and methods 
2.1. Patients
  Three confirmed cases of VL [mean age (46.00依1.73) years] 
admitted to village primary health center, Baniyapur of 
district Saran, State of Bihar, India were included in this 
study. This study area is hyper-endemic region for VL. 
These patients were clinically correlated for VL before the 
start of treatment. The pretreatment basal characteristics 
viz. weight, spleen size, WBC count, hemoglobin and platelet 
counts were (50.33依1.52) kg, (8.07依1.17) cm, (4.3依0.1) x103 
mm3, (8.37依0.32) g/dL and (83 000依11269)/毺L respectively. 
They were treated with miltefosine, available at the primary 
health center, as per recommended guidelines. After 
completion of treatment, increase in weight [(50.66依1.53) kg], 
WBC count [(5.43依0.38)伊103 mm3], hemoglobin[(11.000依0.260) g/dL],
platelet counts (140666依5033) /毺L] and decrease in spleen 
size [(3.13依0.12) cm] were observed. For control, one healthy 
individual (one of the author of this study) from non-
endemic region and one from endemic region without any 
past history of VL were used for urine collection.
2.2. Sample collection
  The twenty four hour urine samples were collected for 
isolation of proteins. On the same day samples were brought 
on ice to Molecular Immunology Laboratory, Department 
of Biochemistry, Banaras Hindu University, Varanasi, and 
processed for isolation of urinary antigens (ULAs). The sera 
were obtained from blood that was collected for routine 
laboratory analysis. 
2.3. Isolation of ULAs
  The urine samples were centrifuged at 5 000 rpm for 10 
min at 4 曟 to remove sediment and debris. The clear urine 
samples were subjected to ammonium sulphate precipitation 
(90%) by adding calculated amount of powdered ammonium 
sulphate according to their percentage saturation directly 
into the urine samples with constant stirring on magnetic 
stirrer at 4 曟 overnight followed by centrifugation at 10 000 
rpm for 10 minutes at 4 曟. Pellets containing the proteins 
were dissolved in small volume of phosphate buffer saline 
(PBS). The isolated proteins were purified by Amicon Ultra 
(Millipore, USA), a 3 kDa molecular weight cutoff membrane 
filtration device. The purified proteins were quantified by 
Lowry method and stored at -80 曟 till further use. 
2.4. SDS-PAGE
  Purified proteins were resolved by SDS-PAGE analysis of 
that was carried out using 12% non gradient slab gel with 
a 5% stacking gel as per standard protocol at 100V for 3.5 
hours by using gel electrophoresis system (Klever Scientific, 
UK).The protein bands were stained with commassie brilliant 
blue (CBB). The gels were visualized and analyzed by gel 
documentation system (Alpha Innotech Corporation, USA) 
using gel densitometry software against known molecular 
weight markers.
2.5. Immunoblotting
  In order to confirm the antigens of leishmanial origin, 
western blot analysis was done. Proteins were transferred 
onto PVDF membrane according to the standard protocol 
in a mini trans-blot electrophoresis transfer cell (Klever 
Scientific, UK) following manufacturer’s protocol. Briefly, 
the membranes were soaked in blocking buffer (5% non-
fat dried milk in a PBS (0.02 M, 0.9% NaCl, 0.1% Tween 
20) for three hours at room temperature [(22依 2) 曟]. After 
three times wash in PBS/Tween 20, the membranes were 
incubated with sera (1:100 dilutions) obtained from patients 
before and after the treatment blocking buffer for 2 hours 
at RT. The membranes were again washed for three times 
to remove unbound antibodies and incubated with a 1:3 000 
dilution of AP-conjugated anti-human immunoglobulin G 
(Sigma, Aldrich, USA) in blocking buffer followed by  three 
additional washes. Color was developed by using the BCIP/
NBT as substrate for alkaline phosphate and reaction was 
stopped by distilled water. The developed membranes were 
photographed after drying and analyzed by Gel documention 
system (Alpha Innotech Corporation, USA) using gel 
densitometry software.
3. Results 
  Eight proteins of molecular weights 17 kDa, 25 kDa, 28 kDa, 
42 kDa, 47 kDa, 54 kDa, 60 kDa, and 85 kDa were detected in 
pretreated urine samples of VL patients. (Figure 1, lane A-C) 
Although, all proteins were detected in all three samples but 
their excretion in urine was differential in terms of quantity 
of proteins. The 85 kDa protein was less excreted in first 
patients. The excretion of 25 kDa antigen was highest in all 
patients. 
  The western blot analysis with patients serum obtained 
prior to treatment confirmed the antigenicity of total four 
urinary proteins of mw 25 kDa, 28 kDa, 54 kDa, and 60 kDa.
(Figure 2 lane A-C). The antibodies against proteins of 
molecular weight 17 kDa, 42 kDa, 47 kDa and 85 kDa were not 
detected in pretreated serum samples. The blot analysis 
with serum samples obtained a day after the completion of 
treatment showed that antibodies against 54 kDa and 60 kDa 
were persistent in serum even after successful treatment 
(Figure 2 lane D-F). These urinary proteins were not reactive 
with serum samples obtained from healthy endemic and 
non-endemic controls. (Figure 2 lane G, H)
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Figure 1. Urinary proteins on 12% SDS-PAGE. Lane M- molecular 
weight marker (7-175kDa); lane A-C: VL patients.
M            A          B           C            D          E            F           G          H
175
80
58
46
30
25
17
7
Figure 2. Immunoblot of urinary proteins with pre and after treatment 
serum samples of patients and controls. 
Lane M: marker (7-175kDa); lane A-C: pretreatment serum, lane 
D-F: post treatment serum, lane G: endemic control, lane H: non-
endemic control.
4. Discussion 
  A common symptom of the renal lesion due to protozoan 
infection is immunodeposits in granular pattern [15], and 
it also results in parasitic antigen release in urine[16]. 
The studies on urinary antigens can be correlated to 
immunopathogenesis & immunoprophylaxis, and it can 
also be beneficial to develop diagnostic and prognostic 
assays with excellent sensitivity & specificity. In spite of 
availability of various serological tests, the major problem 
of current tools for VL is their cross reactivity with other 
diseases like malaria, tuberculosis, sleeping sickness, 
amoebiasis etc, which are co-endemic in affected region[5, 17]. 
  In our previous studies, we have found that up to 32% of 
healthy people without any sign and symptoms of VL could 
be seropositive by these test[5]. In these situations, and 
because of the serious therapeutics implication related to 
an incorrect or late diagnosis of VL, an accurate laboratory 
test is required to confirm the clinical diagnosis[18]. To the 
best of our knowledge, this is the first study that reports 
severe urinary proteinuria in VL patients and implicate their 
circulatory antibodies in patients blood. This study further 
demonstrates the differential excretion of urinary proteins 
that may be correlated with disease severity. Following 
treatment with miltefosine the proteins were disappeared 
in urine, which confirms the temporary presence of urinary 
antigens due to the leishmaniasis.
  Immunoblot analysis using patient’s serum revealed 
that four urinary proteins are immunogenic in nature. 
This is an interesting finding and we are evaluating their 
immunoprohylactic capabilities in context to unavailability 
of a vaccine candidate and a true drug target. Further the 
disappearance of antibodies for 25 kDa and 28 kDa antigens 
offers a greater probability for development of a prognostic 
serological test based on these antigens. However, the 
disappearance of urinary proteins after successful treatment 
seems to be more reasonable to develop diagnostic and 
prognostic tools as the urine based assays are noninvasive 
and facilitates compliance of people in field activities.  
  To conclude and in the context to unavailability of a perfect 
diagnostic and prognostic tool, the urinary leishmanial 
antigens (ULAs) offer a better prospective. However, more 
detailed investigations are required for better understanding 
to develop an accurate diagnostic and prognostic tool, which 
is crucial to establish and implement measures to control 
the spread of this disease in disease endemic countries.    
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